
US FDA Rejects Capricor Duchenne Therapy
The US FDA declined to approve Capricor Therapeutics experimental cell therapy for Duchenne muscular dystrophy due to trial data integrity problems. Company shares dropped sharply in extended trading following the regulatory decision.
Xurve View
Insights:
Xurve View

The United States Food and Drug Administration declined to approve CAPRICOR THERAPEUTICS INC's experimental cell therapy, sending shares plunging 72% in extended trading on Friday afternoon. The rejection is a setback for the biotech firm's lead asset targeting a fatal genetic muscle-wasting condition. Capricor sought approval for the therapy, known as deramiocel, to preserve upper-limb function in Duchenne muscular dystrophy patients.








